Laryngeal Reflex Study Under Propofol Anesthesia: Effect of Intravenous Lidocaine

NCT ID: NCT01222169

Last Updated: 2015-10-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To describe respiratory and laryngeal responses to laryngeal stimulation during propofol anesthesia in children. To determine whether the co-administration of lidocaine blunts these reflex responses. The outcome of primary interest is the reflex laryngospasm.

Hypotheses:

I: The severity of laryngospasm evoked by laryngeal stimulation is reduced 2 min. after iv. administration on 2mg/kg lidocaine in pediatric patients anesthetized with propofol (3mcg/ml).

II:The incidence of laryngospasm elicited by controlled stimulation 10min. after iv. administration of lidocaine is equivalent to the response before the administration of lidocaine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on our previous work assessing the laryngeal reflex responses in children, the use of propofol appears to be promising regarding a low incidence of laryngospasm. Compared with a sevoflurane-based anesthesia, the incidence was found to be significantly lower, but there is a high incidence of other reflex responses, such as coughing and expiration reflexes. The use of lidocaine has been advocated to reduce the incidence of laryngospasm in anesthetized children. However, based on clinical studies its effectiveness in the prevention or attenuation of laryngospasm is controversial.

In a previous work using a established stimulation model (stimulating the laryngeal mucosa with a small amount of distilled water under direct fiberbronchoscopic observation), we observed a risk reduction of 60% of laryngospasm 2min. after the application of 2mg/kg bolus of lidocaine. This effect had already diminished after 10 min.

The laryngeal reflex responses differ largely in children anesthetized with either inhalational anesthetics or with propofol. The impact iv administered lidocaine on laryngeal and respiratory reflex responses in children anesthetized with propofol has not been assessed, although this combination might result in a profound suppression of laryngeal reflex responses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Laryngospasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

larynx assessment under stimulation

Group Type EXPERIMENTAL

NaCl 0,9%

Intervention Type DRUG

Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application

Larynx assessment under stimulation

Group Type PLACEBO_COMPARATOR

NaCl 0,9%

Intervention Type DRUG

Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NaCl 0,9%

Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Propofol Disoprivan Recofol Natriumchlorid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 25 - 84 months
* gender: female / male
* elective surgery or diagnostic procedure requiring general anesthesia

Exclusion Criteria

* respiratory infection within the last 2 weeks
* reactive airway disease under therapy
* cardiovascular disease
* neuromuscular disease
* positive family history of malignant hyperthermia
* known hypersensitivity to the investigational medical product
* Participation in another study
* Inability of the parents to read and understand the participant's information
Minimum Eligible Age

25 Months

Maximum Eligible Age

84 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Thomas Erb

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Thomas Erb

Prof. Dr. Thomas O. Erb

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas O Erb, Professor MD

Role: PRINCIPAL_INVESTIGATOR

University children's hospital beider Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University children's hospital beider Basel

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UKBB_ANA_LR 6

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PK Intravenous Lidocaine Infusion
NCT02241096 TERMINATED PHASE1
IV Lidocaine in Pediatric AIS
NCT03893318 TERMINATED PHASE4